Continuous Dopaminergic Stimulation for Parkinson's Disease

Continuous Dopaminergic Stimulation (CDS) for Parkinson's Disease

<div class="infobox infobox-company">
<div class="infobox-header">CDS Pipeline Overview</div>
<div class="infobox-row"><strong>Delivery Methods:</strong> Infusion, pump, patch</div>
<div class="infobox-row"><strong>Stage:</strong> Approved to Phase 3</div>
<div class="infobox-row"><strong>Target:</strong> Motor fluctuations, dyskinesia</div>
</div>

Overview

Continuous Dopaminergic Stimulation (CDS) for Parkinson's Disease

<div class="infobox infobox-company">
<div class="infobox-header">CDS Pipeline Overview</div>
<div class="infobox-row"><strong>Delivery Methods:</strong> Infusion, pump, patch</div>
<div class="infobox-row"><strong>Stage:</strong> Approved to Phase 3</div>
<div class="infobox-row"><strong>Target:</strong> Motor fluctuations, dyskinesia</div>
</div>

Overview

Continuous dopaminergic stimulation (CDS) is a treatment strategy for Parkinson's disease that provides steady, round-the-clock delivery of dopaminergic medication, addressing the motor fluctuations and dyskinesias that develop with standard oral levodopa therapy["@cds_concept"].

Clinical Rationale

Traditional oral levodopa produces fluctuating dopamine levels:

• Peak concentrations → dyskinesias
• Trough concentrations → "off" episodes

• Stable dopamine receptor stimulation
• Reduced motor complications
• Improved quality of life
• Lower total daily levodopa dose

Delivery Technologies

1. Continuous Subcutaneous Infusion

| Company | Product | Drug | Status |
|---------|---------|------|--------|
| AbbVie | ABBV-951 | Foslevodopa/foscarbidopa | Phase 3/Approved |
| Astellas | ND0612 | Levodopa/carbidopa | Phase 3 |
| Supernus | SPN-830 | Apomorphine | Phase 3 |
| Sunovion | Apomorphine infusion | Apomorphine | Phase 3 |

2. Transdermal Patch

| Company | Product | Drug | Status |
|---------|---------|------|--------|
| UCB | Neupro | Rotigotine | Approved |
| Novartis | Emsam | Selegiline | Approved |
| Mitsubishi Tanabe | Azilect | Rasagiline | Approved |

3. Intestinal Infusion

| Company | Product | Mechanism | Status |
|---------|---------|-----------|--------|
| AbbVie | Duodopa/Duopa | Intestinal gel | Approved |

Key Companies and Programs

AbbVie - ABBV-951 (Crexont)

AbbVie's ABBV-951 is a subcutaneous continuous infusion of foslevodopa/foscarbidopa:

• Mechanism: Prodrugs provide stable levodopa delivery
• Status: Approved (2024)
• Advantage: Reduces "off" time and dyskinesia

Astellas - ND0612

ND0612 is a subcutaneous levodopa/carbidopa infusion system:

• Stage: Phase 3
• Advantage: Eliminates oral medication peaks/troughs
• Benefit: Continuous dopaminergic stimulation

Supernus Pharmaceuticals - SPN-830

SPN-830 provides continuous apomorphine infusion:

• Mechanism: Continuous D1/D2 agonist delivery
• Stage: Phase 3
• Advantage: Non-levodopa approach

UCB - Neupro Patch

Neupro (rotigotine) is a transdermal dopamine agonist patch:

• Mechanism: Continuous 24-hour agonist delivery
• Status: Approved
• Advantage: Non-oral, sustained release

Clinical Benefits

Motor Symptoms

• Reduced "off" time
• Decreased dyskinesia severity
• Improved motor function scores

Quality of Life

• Fewer daily medication doses
• More predictable symptom control
• Greater independence

Disease Modification

Some evidence suggests CDS may slow progression of motor complications through more physiological dopamine receptor stimulation.

Pipeline Summary

| Product | Company | Mechanism | Stage |
|---------|---------|-----------|-------|
| ABBV-951 | AbbVie | Foslevodopa infusion | Approved |
| ND0612 | Astellas | Levodopa infusion | Phase 3 |
| SPN-830 | Supernus | Apomorphine infusion | Phase 3 |
| Neupro | UCB | Rotigotine patch | Approved |
| Duodopa | AbbVie | Intestinal gel | Approved |

Related Mechanisms

• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Levodopa Pharmacokinetics](/therapeutics/levodopa)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatments)
• [Motor Complications](/diseases/parkinsons-disease)

Cross-References

• [PD Pipeline](/companies/pd-pipeline)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Astellas](/companies/astellas)
• [AbbVie](/companies/abbvie)
• [UCB](/companies/ucb)
• [Supernus Pharmaceuticals](/companies/supernus-pharmaceuticals)

External Links

• [PubMed - Continuous Dopaminergic Stimulation](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov - PD Infusion](https://clinicaltrials.gov)
• [Parkinson's Foundation](https://www.parkinson.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Continuous Dopaminergic Stimulation for Parkinson's Disease discovered through SciDEX knowledge graph analysis: